Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 49.14% is in line with its 5-year average of 48.92%, near the high end of its 5-year range (23.58%–54.64%).
0.23% below its 12-month average of 49.25%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 52.40%.
GROSS MARGIN
49.14%
GROSS MARGIN AVG TTM
49.25%
GROSS MARGIN AVG 3Y
49.17%
GROSS MARGIN AVG 5Y
48.92%
GROSS MARGIN AVG 10Y
52.13%
GROSS MARGIN AVG 15Y
56.62%
GROSS MARGIN AVG 20Y
57.34%
CURRENT VS TTM AVG
-0.23%
CURRENT VS 3Y AVG
-0.07%
CURRENT VS 5Y AVG
+0.45%
CURRENT VS 10Y AVG
-5.73%
CURRENT VS 15Y AVG
-13.22%
CURRENT VS 20Y AVG
-14.30%
SECTOR MEDIAN · HEALTHCARE
41.20%
median of 644 covered companies
CURRENT VS SECTOR MEDIAN
+19.26%
vs the sector median at left
Standard BioTools Inc.
Market Cap
$292.34M
Gross Margin
49.14%
TTM Avg
49.25%
3Y Avg
49.17%
5Y Avg
48.92%
Market Cap
$292.79M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$291.83M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$286.16M
Gross Margin
73.68%
TTM Avg
36.84%
3Y Avg
49.00%
5Y Avg
66.00%
Market Cap
$283.44M
Gross Margin
0.00%
TTM Avg
10.38%
3Y Avg
-887.42%
5Y Avg
-730.43%
Market Cap
$307.13M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
25.00%
5Y Avg
13.20%
Market Cap
$278.62M
Gross Margin
42.62%
TTM Avg
48.63%
3Y Avg
38.13%
5Y Avg
25.55%
Market Cap
$280.84M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$276.83M
Gross Margin
-94.12%
TTM Avg
-431.85%
3Y Avg
-231.35%
5Y Avg
-189.25%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Standard BioTools Inc. (LAB) | $292.34M | 49.14% | 49.25% | 49.17% | 48.92% |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $292.79M | 0.00% | 0.00% | 0.00% | 0.00% |
| Larimar Therapeutics, Inc. (LRMR)vs › | $291.83M | 0.00% | 0.00% | 0.00% | 0.00% |
| Abeona Therapeutics Inc. (ABEO)vs › | $286.16M | 73.68% | 36.84% | 49.00% | 66.00% |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $283.44M | 0.00% | 10.38% | -887.42% | -730.43% |
| Benitec Biopharma Inc. (BNTC)vs › | $307.13M | 0.00% | 0.00% | 25.00% | 13.20% |
| Aurora Cannabis Inc. (ACB)vs › | $278.62M | 42.62% | 48.63% | 38.13% | 25.55% |
| Indaptus Therapeutics, Inc. (INDP)vs › | $280.84M | 0.00% | 0.00% | 0.00% | 0.00% |
| Fate Therapeutics, Inc. (FATE)vs › | $276.83M | -94.12% | -431.85% | -231.35% | -189.25% |
| Mobia Medical, Inc. Common Stock (MOBI)vs › | $310.71M | 81.07% | 81.07% | 81.07% | 81.07% |
Gross Margin
49.1%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 52.40% |
| 2026-03-31 | 53.48% |
| 2025-12-31 | 43.03% |
| 2025-09-30 | 48.51% |
| 2025-06-30 | 48.84% |
| 2025-03-31 | 54.64% |
| 2024-12-31 | 46.89% |
| 2024-09-30 | 51.73% |
| 2024-06-30 | 46.12% |
| 2024-03-31 | 53.11% |
| 2023-12-31 | 47.39% |
| 2023-09-30 | 43.97% |
| 2023-06-30 | 49.17% |
| 2023-03-31 | 48.89% |
| 2022-12-31 | 41.33% |
| 2022-09-30 | 35.95% |
| 2022-06-30 | 23.58% |
| 2022-03-31 | 46.17% |
| 2021-12-31 | 52.90% |
| 2021-09-30 | 47.95% |
| 2021-06-30 | 52.94% |
| 2021-03-31 | 58.06% |
| 2020-12-31 | 58.77% |
| 2020-09-30 | 63.52% |
| 2020-06-30 | 58.86% |
| 2020-03-31 | 59.57% |
| 2019-12-31 | 55.14% |
| 2019-09-30 | 52.98% |
| 2019-06-30 | 54.49% |
| 2019-03-31 | 56.42% |
| 2018-12-31 | 58.19% |
| 2018-09-30 | 54.63% |
| 2018-06-30 | 51.42% |
| 2018-03-31 | 53.18% |
| 2017-12-31 | 51.49% |
| 2017-09-30 | 49.23% |
| 2017-06-30 | 49.97% |
| 2017-03-31 | 53.12% |
| 2016-12-31 | 55.19% |
| 2016-09-30 | 53.59% |
| 2016-06-30 | 55.67% |
| 2016-03-31 | 58.68% |
| 2015-12-31 | 59.02% |
| 2015-09-30 | 60.09% |
| 2015-06-30 | 58.19% |
| 2015-03-31 | 60.17% |
| 2014-12-31 | 61.87% |
| 2014-09-30 | 61.46% |
| 2014-06-30 | 63.94% |
| 2014-03-31 | 66.16% |
| 2013-12-31 | 72.19% |
| 2013-09-30 | 71.90% |
| 2013-06-30 | 72.11% |
| 2013-03-31 | 70.70% |
| 2012-12-31 | 72.32% |
| 2012-09-30 | 72.48% |
| 2012-06-30 | 69.68% |
| 2012-03-31 | 67.60% |
| 2011-12-31 | 69.16% |
| 2011-09-30 | 68.81% |
| 2011-06-30 | 71.96% |
| 2011-03-31 | 66.51% |
| 2010-12-31 | 65.41% |
| 2010-09-30 | 71.01% |
| 2010-06-30 | 63.85% |
| 2010-03-31 | 60.62% |
| 2009-12-31 | 59.57% |
| 2008-12-31 | 0.00% |
| 2008-06-30 | 0.00% |
| 2007-12-31 | 0.00% |
